Back to Search Start Over

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

Authors :
Antoinette Moran
S. Alice Long
Susan Geyer
Megan V. Warnock
Linda A. DiMeglio
Henry Rodriguez
Jennifer B. Marks
Dorothy J. Becker
David A. Baidal
J Lori Blanchfield
Darrell M. Wilson
Peter A. Gottlieb
Stephen E. Gitelman
Desmond A. Schatz
Brian N. Bundy
Jessica L. Miller
Mark A. Atkinson
Michael J. Haller
Jay S. Skyler
Carla J. Greenbaum
Robin Goland
Jeffrey P. Krischer
Kevan C. Herold
William E. Russell
Source :
Diabetes
Publication Year :
2019
Publisher :
American Diabetes Association, 2019.

Abstract

A three-arm, randomized, double-masked, placebo-controlled phase 2b trial performed by the Type 1 Diabetes TrialNet Study Group previously demonstrated that low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg) preserved β-cell function and reduced HbA1c for 1 year in new-onset type 1 diabetes. Subjects (N = 89) were randomized to 1) ATG and pegylated granulocyte colony-stimulating factor (GCSF), 2) ATG alone, or 3) placebo. Herein, we report 2-year area under the curve (AUC) C-peptide and HbA1c, prespecified secondary end points, and potential immunologic correlates. The 2-year mean mixed-meal tolerance test–stimulated AUC C-peptide, analyzed by ANCOVA adjusting for baseline C-peptide, age, and sex (n = 82) with significance defined as one-sided P < 0.025, was significantly higher in subjects treated with ATG versus placebo (P = 0.00005) but not ATG/GCSF versus placebo (P = 0.032). HbA1c was significantly reduced at 2 years in subjects treated with ATG (P = 0.011) and ATG/GCSF (P = 0.022) versus placebo. Flow cytometry analyses demonstrated reduced circulating CD4:CD8 ratio, increased regulatory T-cell:conventional CD4 T-cell ratios, and increased PD-1+CD4+ T cells following low-dose ATG and ATG/GCSF. Low-dose ATG partially preserved β-cell function and reduced HbA1c 2 years after therapy in new-onset type 1 diabetes. Future studies should determine whether low-dose ATG might prevent or delay the onset of type 1 diabetes.

Details

Language :
English
ISSN :
1939327X and 00121797
Volume :
68
Issue :
6
Database :
OpenAIRE
Journal :
Diabetes
Accession number :
edsair.doi.dedup.....e408ecd37f3201a76d7f54cd07b1a446